Dr Reddy's, Zydus Lifesciences to co-market Pertuzumab biosimilar in India
Zydus Lifesciences has entered into a licensing agreement with Dr Reddy’s Laboratories to co-market in India the Pertuzumab biosimilar, a critical treatment for HER2 positive breast cancer, per a CNBC report.
The biosimilar, which was developed in-house by Zydus' research team at the Zydus Research, represents a significant advancement in breast cancer therapy. Under the terms of the agreement, Zydus will market the product under the brand name Sigrima, while Dr Reddy will market it as Womab.
Dr Reddy's will receive semi-exclusive rights from Zydus to co-market the product in India. Zydus will receive upfront licensing income and is eligible to receive milestone income based on the achievement of pre-defined milestones, the report said. The outlet also reported that the collaboration aims to broaden access to this essential medication for patients across India, leveraging the strengths of both companies in distribution and market reach.
[Read more: Dr. Reddy's acquires MenoLabs from Amyris]
The report offered the following comment froma Zydus Lifesciences spokesperson: "Our basket of cancer care therapies which includes cytotoxic, supportive and targeted drugs, has had a significant impact on patient survival and the quality of life. We are committed to providing comprehensive care for HER2-positive patients and with the launch of this critical drug, we will be offering all three essential drugs, Sigrima, Pertuzumab biosimilar, Vivitra the largest selling trastuzumab biosimilar and Ujvira the world’s first antibody-drug conjugate biosimilar of trastuzumab emtansine."
[Read more: Challenges continue, but generics companies see a bright future with biosimilars]